Core Viewpoint - China SXT Pharmaceuticals, Inc. has regained compliance with Nasdaq's Minimum Bid Price Requirement after a share consolidation, closing the matter with Nasdaq [1][4]. Group 1: Compliance Notification - The company received a Compliance Notice from Nasdaq on March 13, 2025, confirming it has met the Minimum Bid Price Requirement [1][4]. - Previously, on October 3, 2024, the company was notified of its failure to maintain a minimum bid price of US$1.00 per share for 30 consecutive business days [2]. Group 2: Share Consolidation - To address the Minimum Bid Price deficiency, the company executed a share consolidation on February 25, 2025, consolidating every eight ordinary shares into one [3]. - Following the consolidation, the company achieved a closing bid price of at least US$1.00 per share for 10 consecutive business days from February 25, 2025, to March 12, 2025 [4]. Group 3: Company Overview - China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou City, Jiangsu Province, China, focusing on Traditional Chinese Medicine Pieces [5].

TAIZHOU, China, March 17, 2025 (GLOBE NEWSWIRE) -- China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) (the "Company"),  a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements ("TCMHS"), today announced that the Company received a written notification (the "Compliance Notice") fr ...

Core Viewpoint - China SXT Pharmaceutics, Inc. will implement a share consolidation at a ratio of 1-for-8 effective February 25, 2025, to comply with Nasdaq's minimum bid price requirement of $1.00 per share [1][2]. Company Actions - The Board of Directors approved the share consolidation to regain compliance with Nasdaq's minimum bid price requirement, which necessitates a closing bid price of $1.00 or more for at least ten consecutive trading days by April 1, 2025 [2]. - Following the share consolidation, every eight shares will be consolidated into one ordinary share, with no fractional shares issued; any fractional shares will be rounded up to one ordinary share [3]. Shareholder Impact - Shareholders holding shares through banks, brokers, or other nominees will have their shares automatically adjusted to reflect the consolidation [4]. - Beneficial holders are advised to contact their bank, broker, or nominee for further information regarding the share consolidation [4]. Company Overview - China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company established in 2005, focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces [5].

Financial Performance - For the fiscal year ended March 31, 2024, total revenue decreased by 2% to $1,928,497 compared to $1,971,679 in the previous fiscal year[180]. - The net loss for the fiscal year ended March 31, 2024, decreased by 48% to $3,098,532 from $5,934,772 in the previous fiscal year[180]. - Total revenues for the year ended March 31, 2024, were $1,928,497, a decrease of $43,182 or 2% compared to $1,971,679 for the year ended March 31, 2023[303]. - Gross profit increased by $127,700 or 30% to $553,971 for the year ended March 31, 2024, with a gross margin of 28.7% compared to 21.6% for the previous year[313]. - Total operating expenses decreased by $2,964,592 or 49% to $3,069,188 for the year ended March 31, 2024, primarily due to a significant reduction in general and administrative expenses[303]. - General and administrative expenses decreased by $3,010,706 or 53% to $2,635,622, mainly due to reduced payroll expenses and a 90% decrease in credit loss provisions[316]. - Loss from operations improved by $3,092,292 or 55% to $2,515,217 for the year ended March 31, 2024[303]. - The company generated $13,150 in revenue from a new health beverage product, contributing 1% to total revenue for the year ended March 31, 2024[311]. - The company’s total comprehensive loss for the year ended March 31, 2024, was $3,926,756, compared to $7,088,485 for the year ended March 31, 2023[344]. - The company experienced a continuous decline in revenue for the years ended March 31, 2024, 2023, and 2022, raising substantial doubt about its ability to continue as a going concern[364]. Product Development and R&D - Advanced TCMP products accounted for 49.1% of total revenue for the fiscal year ended March 31, 2024, up from 33.3% in the fiscal year ended March 31, 2023[179]. - The company has developed and marketed 11 Advanced TCMP products, 5 Fine TCMP products, and 200 Regular TCMP products[179]. - The company has decided to discontinue cooperation with major clients in the sales of Fine TCMP and will not develop or sell Fine TCMP products in the future[206]. - The company has a product portfolio of 11 Advanced TCMP products, 5 Fine TCMP products, 200 Regular TCMP products, and 200 raw medicinal materials[207]. - The R&D team has submitted 8 patent applications and 4 invention patent applications, all under substantive examination, focusing on preparation process patents[216]. - The company’s R&D strategy aims to revolutionize TCMP production using advanced technology, including e-beam processing which improved bioavailability by 15%[218][219]. - The company has established a strong R&D team of 13 researchers, focusing on innovative TCMP products that simplify administration for customers[249]. - The company has successfully commercialized multiple modernized TCMPs without the need for additional regulatory approvals[249]. Market and Customer Base - The customer base includes 57 pharmaceutical companies, 14 chain pharmacies, and 16 hospitals across five provinces in China[182]. - As of March 31, 2024, the company’s end-customer base includes 57 pharmaceutical companies, 14 chain pharmacies, and 16 hospitals across 5 provinces[214]. - The company currently contracts with over 102 distributors in the PRC and plans to expand its distribution network to increase market penetration[254]. - The company operates 4 sales offices covering 12 major provinces in China, with over 68 sales representatives managing distributor relationships[215]. Financial Structure and Compliance - The company operates under a VIE structure, consolidating the financial results of Taizhou Suxuantang in accordance with U.S. GAAP[176]. - The company has not distributed any earnings or settled amounts owed under the VIE Agreements as of the date of the annual report[191]. - The company is subject to a 10% withholding tax on dividends paid by WFOE to SXT HK, which may be reduced to 5% under certain conditions[199]. - The company has conducted foreign exchange registration under existing PRC regulations, allowing its PRC subsidiary to legally distribute earnings[201]. - The company has established contractual arrangements with Taizhou Suxuantang to consolidate financial results under U.S. GAAP due to PRC legal restrictions on foreign ownership[282]. Production and Manufacturing - The company reconstructed an 850-square-meter facility in December 2018 for TCMHS production and received a Food Manufacturing Certificate[222]. - The company has extended its production facility for lyophilization processing, enhancing its capability to produce temperature-sensitive TCMP products[222]. - The company operates GMP-certified facilities totaling approximately 1,200 square meters for Regular TCMP production and 450 square meters for Fine TCMP production[294]. - The company holds a Pharmaceutical Manufacturing Permit from the NMPA, valid until December 17, 2025[239]. - The company is GMP certified, ensuring compliance with strict quality control and assurance standards in pharmaceutical manufacturing[236]. Intellectual Property - The company holds 28 utility model and invention patents, with a validity period of 20 years from the application date[225]. - The company has submitted five additional invention patent applications recently, enhancing its intellectual property portfolio[227]. - There are currently four invention patent applications under substantive examination at the State Intellectual Property Office of PRC[181]. Strategic Goals and Future Plans - The company plans to enhance collaboration with universities and research institutes for joint R&D projects related to TCMP processing methods and quality standards[181]. - The company intends to retain future earnings to finance business expansion and does not anticipate paying cash dividends in the foreseeable future[196]. - The company aims to promote its existing brand to increase national recognition and maintain a branded pricing strategy through marketing efforts[252]. - The company is focused on developing and introducing additional Advanced TCMP products to strengthen its existing product portfolio[253]. Challenges and Risks - The company competes with established pharmaceutical companies in the TCMP market, which have greater resources and market presence[242]. - The management team has extensive experience in the pharmaceutical industry, with most members having over 10 years of relevant experience[250]. - The company experienced a significant increase in cash outflow from operating activities, with net cash used amounting to $1,928,053 for the year ended March 31, 2024, compared to $80,757 for the year ended March 31, 2023[352].

Financial Performance - For the fiscal year ended March 31, 2023, net revenues decreased by 24% to $1,971,679 from $2,602,281 in the previous fiscal year[175]. - The net loss for the fiscal year ended March 31, 2023, increased by 3% to $5,934,772 compared to a net loss of $5,736,095 in the prior year[175]. - Total revenues for the year ended March 31, 2023, were $1,971,679, a decrease of $630,602 or 24% compared to $2,602,281 for the year ended March 31, 2022[298]. - Gross profit for the year ended March 31, 2023, was $426,271, down from $1,251,643 in the previous year, representing a decline of 66%[298]. - Loss from operations increased to $5,607,509 for the year ended March 31, 2023, compared to $5,189,673 for the year ended March 31, 2022, an increase of 8%[298]. - Interest expense net rose significantly to $476,776 in 2023 from $36,695 in 2022, marking a 1,199% increase[298]. - The accumulated deficit as of March 31, 2023, was $21,613,133, up from $15,688,278 as of March 31, 2022[344]. - The company has raised substantial doubt about its ability to continue as a going concern due to ongoing losses and declining revenues[359]. Revenue Breakdown - Advanced TCMP products accounted for 33.3% of total revenue for the fiscal year ended March 31, 2023, down from 44.7% in the previous year[174]. - Revenue from Advanced TCMP decreased by $506,180, or 44%, accounting for 33% of total revenue for the year ended March 31, 2023[302]. - Revenue from Fine TCMP decreased by $284,976, or 71%, representing 6% of total revenue for the year ended March 31, 2023[303]. - Revenue from Regular TCMP decreased by $95,912, or 12%, accounting for 35% of total revenue for the year ended March 31, 2023[304]. - Revenue from raw medicinal materials was $502,425, representing 25% of total revenue for the year ended March 31, 2023[306]. Operational Developments - The company has developed and introduced a total of 17 Advanced TCMP products, 5 Fine TCMP products, and 87 Regular TCMP products as of the date of the annual report[174]. - The company plans to enhance cooperation with universities and research institutes for joint R&D projects related to TCMP processing methods and quality standards[176]. - The company has established a production facility for lyophilization processing, enhancing the quality and shelf life of its products[219]. - The company has a well-functioning production and sales network with 5 major suppliers in key TCM provinces[210]. - The company has been expanding its production base since October 2017, covering a total land area of 33,300 square meters to meet growing demand for TCMPs[288]. Research and Development - The R&D team has submitted 8 patent applications and 4 invention patent applications, all under substantive examination, focusing on preparation process patents[213]. - The company has achieved a 15% increase in bioactive compound extraction efficiency through e-beam processing compared to regular extraction methods[216]. - The research and development team consists of 15 dedicated researchers, focusing on innovative TCMP products that simplify administration for customers[244]. - The company intends to introduce new Advanced TCMP products steadily to strengthen its market leadership position in Directly-Oral and After-Soaking-Oral TCMPs[248]. Regulatory Compliance - The company’s operations are subject to PRC laws and regulations, which may pose risks related to foreign ownership and regulatory compliance[172]. - The company has obtained all necessary business licenses from the State Administration for Market Regulation for its operations[178]. - The VIE entity has obtained the required licenses and permits for pharmaceutical manufacturing, but compliance with GMP standards is critical for ongoing operations[179]. - The company complies with China's Environmental Protection Law and has not faced any penalties for non-compliance in the past[225]. - The production of Traditional Chinese Medicine Products (TCMP) must comply with the "Pharmaceutical Administration Law of PRC (2019 Revision)" and GMP standards[257]. Employee and Management Information - As of March 31, 2023, the company had a total of 78 full-time employees, with a focus on maintaining a qualified workforce for manufacturing and quality control[250]. - The company has signed confidentiality agreements with all employees to protect its production design and intellectual property[222]. - Information regarding directors, executive officers, and key employees is provided, indicating a structured management team[367]. Future Outlook - The company intends to retain future earnings to finance business expansion and does not anticipate paying cash dividends in the foreseeable future[191]. - The company is seeking to raise capital through additional debt and equity financings to fund operations for the next 12 months[344]. - The company plans to expand its distribution network, currently contracting with over 102 distributors in the PRC, to increase market penetration[249].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _____________. OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 ...

Financial Performance - Operating revenue for the year ended March 31, 2019, was $7,012,026, a slight decrease from $7,019,243 in 2018[15] - Gross profit for the year ended March 31, 2019, was $4,611,535, compared to $3,401,495 in 2018, indicating a significant increase[15] - Net income attributable to China SXT Pharmaceuticals, Inc. for the year ended March 31, 2019, was $1,539,227, up from $1,187,581 in 2018, representing a growth of approximately 29.5%[15] - Total assets as of March 31, 2019, were $17,470,833, an increase from $7,657,894 in 2018, reflecting a growth of approximately 128.5%[15] - Total liabilities as of March 31, 2019, were $6,363,078, compared to $4,372,119 in 2018, indicating an increase of about 45.4%[15] - Cash and cash equivalents as of March 31, 2019, were $9,130,849, a significant increase from $560,252 in 2018[15] - Total shareholders' equity as of March 31, 2019, was $11,107,755, up from $3,285,775 in 2018, showing an increase of approximately 237.5%[15] Investment and Financing - The company completed a private placement on May 2, 2019, raising $15 million through Senior Convertible Notes and Warrants[20] - The company is currently negotiating with investors regarding forbearance and release agreements due to default notices received[23] - Failure to meet obligations under the Transaction Documents could adversely affect the company's cash flow and expansion plans[25] Operational Challenges - The company relies heavily on a small number of customers, which could adversely affect its revenue if significant contracts are not renewed or replaced[47] - The company faces intense competition from established competitors with greater resources, which may hinder its ability to generate revenue[46] - The company must attract and retain qualified personnel, as competition for talent in the PRC is intense and the pool of qualified candidates is limited[51] - The company has limited operating history in its significant business lines, making it difficult to evaluate future prospects[41] - The company’s success depends on its ability to protect its intellectual property, including patents and trademarks, which may not be adequately enforced[56] - The company does not carry product liability insurance, exposing it to significant financial risks from potential product liability claims[60] Research and Development - The company must consistently invest in research and development to discover and commercialize new TCMP products to remain competitive[62] - The company has submitted eight invention patent applications regarding Advanced TCMP to the State Intellectual Property Office of the PRC in Spring 2017[164] - The R&D team has submitted 13 invention patent applications, with 5 accepted by the State Intellectual Property Office of the PRC[177] - Recent research indicated that e-beam processing improved the bioavailability of certain TCMP forms by 15% compared to regular extraction methods[180] - The company has received three national awards for its R&D in Directly-Oral TCMP and After-Soaking-Oral TCMP products, highlighting its leading position in the industry[181] Regulatory and Compliance Risks - The company is required to meet GMP standards and renew its GMP certification every five years, with the current certification expiring in 2019[64] - The company faces potential adverse effects on revenue and profitability due to price control regulations imposed by the PRC government, which have historically led to price reductions on thousands of pharmaceutical products since May 1998[68] - If the company fails to maintain necessary licenses, permits, and certifications, it could have a material adverse effect on its business and financial condition[65] - Changes in regulations or the introduction of new requirements for licenses and permits could disrupt the company's operations and affect profitability[65] - The company may face scrutiny by PRC tax authorities regarding related party transactions, which could lead to additional tax liabilities[82] Market and Competitive Landscape - The company faces competition from established pharmaceutical companies but believes it is well-positioned due to its brand recognition and diversified product portfolio[202][203] - The advanced TCMP products can be administered orally without the complex decoction process, providing a competitive edge in the market[172] - The company focuses on high-incidence and high-mortality conditions in the PRC, including cardiovascular and CNS diseases[172] Corporate Structure and Governance - The company is classified as an "emerging growth company" under the JOBS Act, which allows it to avoid certain reporting requirements for up to five years, unless it exceeds $1.07 billion in revenues or $700 million in market value[94] - The company will not be required to provide an auditor's attestation report on internal control over financial reporting while it remains an emerging growth company[94] - The company may lose its foreign private issuer status if more than 50% of its Ordinary Shares are held by U.S. residents, which would result in increased legal and compliance costs[104] Brand and Market Positioning - The company aims to enhance the national recognition of its brand "Suxuantang," which has a solid reputation in Eastern China, particularly Jiangsu Province[211] - The company plans to promote the efficacy and safety profiles of its Advanced TCMP products to physicians through various channels, including sales force and educational conferences[211] Economic and Political Environment - Adverse changes in political and economic policies of the PRC government could materially affect the overall economic growth of China, reducing demand for the company's products[121] - The PRC government maintains significant control over economic growth, which could impact the company's growth rate and strategy[122] - Governmental control over currency conversion may restrict the company's ability to remit foreign currency and pay dividends[140]